Tuberculosis risk in the biologic era: tuberculin skin test conversion rates in children with rheumatologic diseases

Background. The widespread use of biological treatments has increased the frequency of opportunistic infections such as tuberculosis (TB). The primary objective of our study was to determine the rate of tuberculin skin test (TST) conversion during biological therapy. The secondary objective was to monitor the side effects related to isoniazid (INH) prophylaxis, in the selected subgroup. Methods. Children with rheumatologic diseases receiving treatment with tumor necrosis factor-alpha (TNF-α) inhibitors, and tocilizumab and canakinumab were included in the study. If baseline screening was negative, TST was performed annually after initiation of biologic therapy. TST conversion was accepted as an increase of at least 6 mm and becoming positive or an increase of 10 mm or more, even in the absence of positivity. Results. 121 patients (female n: 63, 52%) were included in the study. The mean follow-up period was 26.10±14.8 months. 85 of the patients were using TNF-α inhibitors and 18 tocilizumab, and 18 canakinumab. Forty patients had positive TST before biological agents and received chemoprophylaxis with INH. The rate of TST conversion among the 3 biological agents was not statistically significant (20.4% of TNF-α inhibitors, 25% of canakinumab and 33.3% of tocilizumab users). All patients with LTBI received INH prophylaxis, and none of them had active TB. Conclusions. There was no statistically significant difference among the three biological agents, regarding the seroconversion rates. Patients receiving tocilizumab and canakinumab should also be screened for TB during follow-up. INH related side effects are rare.

___

1. World Health Organization (WHO). Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: World Health Organization, 2018. Available at: https://apps.who.int/iris/bitstream/han dle/10665/260233/9789241550239-eng.pdf (Accessed on June 30, 2020).

2. Dobler CC. Biologic agents and tuberculosis. Microbiol Spectr 2016; 4: TNMI7-0026-2016. https:// doi.org/10.1128/microbiolspec.TNMI7-0026-2016

3. Cuomo G, D’Abrsca V, Iacono D, Pantano I. The conversion rate of tuberculosis screening tests during biological therapies in patients with rheumatoid arthritis. Clin Rheumatol 2017; 36: 457-461. https:// doi.org/10.1007/s10067-016-3462-

4. Woerner A, Ritz N. Infections in children treated with biological agents. Pediatr Infect Dis J 2013; 32: 284- 288. https://doi.org/10.1097/INF.0b013e3182833cbb

5. T.C. Sağlık Bakanlığı. Tüberküloz Tanı ve Tedavi Rehberi. Ankara, 2019. Available at: https://hsgm. saglik.gov.tr/depo/birimler/tuberkuloz_db/ haberler/Tuberkuloz_Tani_Ve_Tedavi_Rehberi_/ Tuberkuloz_Tani_ve_Tedavi_Rehberi.pdf (Accessed on July 9, 2019).

6. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24(Suppl 2): S21-S40. https:// doi.org/10.1016/j.cmi.2018.02.002

7. Keystone EC, Papp KA, Wobeser W. Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. J Rheumatol 2011; 38: 1234-1243. https://doi. org/10.3899/jrheum.100623

8. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009; 36: 2158-2163. https://doi.org/10.3899/jrheum.090150

9. Sanduzzi A, Bocchino M, Atteno M, et al. Screening and monitoring of latent tubercular infection in patients taking tumor necrosis factor-α blockers for psoriatic arthritis. J Rheumatol Suppl 2012; 89: 82-85. https://doi.org/10.3899/jrheum.120252

10. Cerda OL, de los Angeles Correa M, Granel A, et al. Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy. Eur J Rheumatol 2019; 6: 19-22. https://doi. org/10.5152/eurjrheum.2018.18096

11. Acar M, Sütçü M, Aktürk H, et al. Tuberculosis screening in pediatric patients receiving TNF-alpha inhibitor therapy. Turk J Pediatr 2017; 59: 503-510. https://doi.org/10.24953/turkjped.2017.05.001

12. Kilic O, Kasapcopur O, Camcioglu Y, Cokugras H, Arisoy N, Akcakaya N. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease? Rheumatol Int 2012; 32: 2675-2679. https://doi.org/10.1007/s00296-011-2030-8

13. Hatzara C, Hadziyannis E, Kandili A, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. Ann Rheum Dis 2015; 74: 1848-1853. https://doi.org/10.1136/ annrheumdis-2014-205376

14. American Thoracic Society. CDC targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(4 Pt 2): S221-S247. https://doi.org/10.1164/ajrccm.161. supplement_3.ats600

15. Garcovich S, Ruggeri A, D’Agostino M, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: a prospective, observational study. J Eur Acad Dermatol Venereol 2012; 26: 1572-1576. https:// doi.org/10.1111/j.1468-3083.2011.04220.x

16. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-806. https:// doi.org/10.1002/art.23705

17. Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012; 14: R147. https://doi.org/10.1186/ar3882

18. Papay P, Primas C, Eser A, et al. Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Aliment Pharmacol Ther 2012; 36: 858-865. https://doi. org/10.1111/apt.12037

19. Scrivo R, Sauzullo I, Mengoni F, et al. Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome. J Rheumatol 2013; 40: 157-165. https://doi.org/10.3899/jrheum.120688

20. Gülez N, Makay B, Sözeri B. Long-term effectiveness and safety of canakinumab in pediatric familial Medıterranean fever patients. Mod Rheumatol 2020; 30: 166-171. https://doi.org/10.1080/14397595.2018.15 59488

21. Kiray E, Kasapcopur O, Bas V, et al. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol 2009; 36: 2029-2032. https://doi. org/10.3899/jrheum.090173

22. Hanta I, Ozbek S, Kuleci S, Sert M, Kocabas A. Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. Clin Rheumatol 2007; 26: 1867- 1870. https://doi.org/10.1007/s10067-007-0591-4

23. Mutlu P, Sevinç C, Uz Kılınç O, Uçan ES. Anti-TNF- alfa tedavisi verilen olgularda latent tüberküloz infeksiyonu açısından izlem sonuçlarımız. Nobel Medicus 2014; 10: 47-52
Turkish Journal of Pediatrics-Cover
  • ISSN: 0041-4301
  • Yayın Aralığı: Yılda 6 Sayı
  • Başlangıç: 1958
  • Yayıncı: Hacettepe Üniversitesi Çocuk Sağlığı Enstitüsü Müdürlüğü
Sayıdaki Diğer Makaleler

Predictive factors of high-flow nasal cannula oxygen therapy failure in children with respiratory distress treated in a Pediatric Emergency Department

Orkun AYDIN, Elif Arslanoğlu AYDIN, Ahmet Zİya BİRBİLEN, Özlem TEKŞAM

The relationship between immature platelet fraction and severity of acute bronchiolitis

Murat DOĞAN, Mehmet KÖSE, Mehmet Adnan ÖZTÜRK, Melih HANGÜL, Hümeyra ASLANER

Covid-19 in a patient with Familial Hemophagocytic Lymphohistiocytosis in children

V. Hülya ÜZEL, Kamil YILMAZ

Primary spinal multifocal intradural-extramedullary Ewing sarcoma in children: presentation of a case and review of the literature

Eren MÜNGEN, Nilgün KURUCU, Tezer KUTLUK, Kader K. OĞUZ, Figen SÖYLEMEZOĞLU, Bilgehan YALÇIN

Clinical follow-up of children with high vitamin B12 values: should we worry?

Davut ALBAYRAK, Canan ALBAYRAK

Short and long term side effect of colistin treatment in preterm infants

Sadık YURTTUTAN, Burcu Cantay ATALAY

Clinical characteristics, late effects and outcomes in pineoblastomas in children: a single center experience

Ömer GÖRGÜN, Başak KOÇ, Rejin KEBUDİ, Johannes E WOLFF, Abut KEBUDİ, Emin DARENDELİLER

Cerebral sinovenous thrombosis in children: clinical presentation, locations, and acquired and inherited prothrombotic risk factors

Yeter Düzenli KAR, Zeynep Canan ÖZDEMİR, Kürşat Bora ÇARMAN, Coşkun YARAR, Neslihan TEKİN, Özcan BÖR

Thiol / disulfide balance and oxidative stress parameters in pediatric patients diagnosed with acute and chronic idiopathic thrombocytopenic purpura

Yeter DÜZENLİ KAR, Zeynep Canan ÖZDEMİR, Özcan BÖR

A case of pediatric psoriasis achieving remission after allogenic bone marrow transplantation

Dilara GÜLER, Gülhan GÜREL, Gülsüm Şeyma YALÇIN, İbrahim EKER, İrem Nur DURUSU, Çiğdem ÖZDEMİR, Özge VURAL